Opexa Therapeutics Reveals Steady Progress Of Phase IIb Trial Of Tovaxin And Recommendation Of Data Safety Monitoring Board - Quick Facts
Tuesday, September 11, 2007; Posted: 07:48 AM
(RTTNews) - Opexa Therapeutics, Inc. (OPXA | charts | news | PowerRating) on Tuesday revealed additional details on its 150-patient Phase IIb safety and efficacy study or TERMS study of Tovaxin in multiple sclerosis
In the multicenter, randomized, double blind, placebo-controlled TERMS study all 150 patients have received their first vaccine dose in the five dose vaccine series and more than 60% of the total 750 vaccine doses of the study have been delivered, the company said.

In addition, the company noted that the Data Safety Monitoring Board has met three times and reported no safety issues and recommends continuing the trial as planned.

Commenting on the recent highlights of the trial, the company's president and chief executive officer, David McWilliams said, "We are encouraged that the diverse myelin peptide reactive profile of each patient that we have identified thus far in the study brings us closer to realizing the promise of individual therapy in general, and specifically supports our individualized therapy approach to the treatment of multiple sclerosis."

For comments and feedback: contact editorial@rttnews.com Copyright(c) 2007 RealTimeTraders.com, Inc. All Rights Reserved

Related Articles

• OPXA: Updates Ph IIb Trial of Tovaxin(R) in Multiple Sclerosis
• Opexa Therapeutics Gives Update on Phase IIb Trial of Tovaxin(R) for Treatment of Multiple Sclerosis
• Opexa Says Its Safety Board Recommends For Continuation Of Phase IIb Study Of Tovaxin In Multiple Sclerosis
• Opexa Therapeutics Reveals Steady Progress Of Phase IIb Trial Of Tovaxin And Recommendation Of Data Safety Monitoring Board - Quick Facts
• *Opexa Therapeutics Gives Update On Phase IIb Trial Of Tovaxin For Treatment Of Multiple Sclerosis
• Opexa Therapeutics To Present At Vaccine Conference; Webcast At 8:35 AM
• Pharma Sector: Few Newsmakers Of The Week - Pfizer, Opexa, Onyx, Panacos, Encysive Pharma, AstraZeneca, Schering-Plough, Bristol-Myers
• Opexa Reports Positive Results In Phase I/II Extension Clinical Trial Of Tovaxin For Multiple Sclerosis - Update
• Opexa Therapeutics Reveals Positive Top-Line Data In Phase I/II Extension Trial With Tovaxin - Quick Facts
• *Opexa Therapeutics Announces Positive Top-Line Data In Phase I/II Extension Trial With Tovaxin

http://www.tradingmarkets.com/.site/news/BREAKING NEWS/596680/